Umbilical cord tissue mesenchymal stromal cells (MSCs) are derived from Wharton’s jelly—the gel-like connective tissue surrounding the umbilical vessels—after a healthy, full-term birth. Sourced from discarded birth tissue without donor procedures, these neonatal cells exhibit a higher proliferative capacity and faster culture expansion than adult bone marrow MSCs, making them a focus in regenerative medicine manufacturing.
Neonatal Cord Tissue Cells Expand Faster than Adult Cells
- What Cord Tissue MSCs Are: These are stromal cells isolated from Wharton’s jelly in the umbilical cord, completely separate from the blood-forming cells found in cord blood.
- Why Source Age Matters: Neonatal cord tissue allows cells to expand faster and further in the lab than cells harvested from older adult donors.
- Lot-Level Testing Requirements: Tissue source is merely a starting point; every manufacturing batch must undergo screening for viability, sterility, and adherence to minimal identity criteria set by the International Society for Cellular Therapy.
Sourcing Comparison Between Bone Marrow, Adipose, and Wharton’s Jelly
When evaluating cell therapy inputs, researchers look closely at where mesenchymal stromal cells originate. Historically, adult bone marrow served as the reference source via invasive aspiration procedures. However, Stolzing and colleagues (2008) reported documented age-related declines in bone marrow MSC numbers and expansion rates. Adipose tissue, typically gathered via liposuction or surgical collection, offers an abundant alternative, though characteristics vary depending on the individual donor and collection technique (Hass 2011).
In contrast, neonatal umbilical cord tissue collected from Wharton’s jelly bypasses the issue of donor aging. According to comparative research by Troyer and Weiss (2008) alongside Baksh and colleagues (2007), Wharton’s jelly-derived MSCs expand faster and achieve higher population doublings in culture than adult bone marrow MSCs. Because the tissue is retrieved after a healthy birth from material that would otherwise be discarded, the donation process involves no clinical procedure on the donor.
| Cell Source | Donor Age | Collection Method | Published Expansion Profile |
|---|---|---|---|
| Bone Marrow | Adult | Aspiration procedure | Historical reference; shows age-related growth declines (Stolzing 2008) |
| Adipose Tissue | Adult | Liposuction or surgery | Abundant yield; characteristics vary by donor (Hass 2011) |
| Umbilical Cord Tissue (Wharton’s Jelly) | Neonatal | Recovered from discarded birth tissue | Higher proliferative capacity and faster expansion than adult sources (Baksh 2007) |
Regulatory Eligibility Standards and Laboratory Isolation Methods
Manufacturing clinical-grade cellular products requires strict adherence to federal regulations. Under 21 CFR Part 1271, Subpart C, human cells and tissue-based products must undergo donor eligibility determinations. For birth tissue, this evaluation involves reviewing the medical and social history alongside communicable-disease testing. Once the tissue reaches a compliant laboratory, technicians isolate the stromal cells from Wharton’s jelly using either explant culture or enzymatic digestion with agents like collagenase and trypsin, as detailed by Salehinejad and colleagues (2012).
To qualify as mesenchymal stromal cells, populations must satisfy minimal criteria established by the International Society for Cellular Therapy (Dominici 2006). Salehinejad and colleagues found that Wharton’s jelly cells express surface markers including CD105, CD73, and CD90, and lack markers such as CD45 and CD34.
Allogeneic Induced Pluripotent Stem Cell Derivation Advantages
Expanding on the utility of birth tissues, research highlights the strategic shift toward using umbilical cord tissue mesenchymal stromal cells (CT-MSCs) for generating induced pluripotent stem cells (iPSCs). While autologous cells offer a match for the patient, utilizing cells from older patients introduces safety hurdles, including accumulated DNA mutations and decreased reprogramming efficiency. Conversely, CT-MSCs provide a source of young donor cells that are less expensive and easier to harvest than cord blood cells (UCBs), bypassing the need for complex column enrichment or flow cytometry.
Integration-free reprogramming methods, such as episomal vectors, allow for the removal of reprogramming factors after a few passages, mitigating mutagenesis risks. Data indicates that CT-MSCs can be efficiently isolated without expensive enzymatic treatments, positioning them as a viable source of clinical-grade donor cells for patient-matched regenerative protocols.
Stem Nova Vials Are Not FDA Approved Drugs
Individualized biological products—such as Stem Nova’s 25M hUCT-MSC vial, which contains 25 million umbilical cord tissue-derived MSCs with 97 percent post-thaw viability manufactured in an FDA-registered, cGTP-compliant facility—are not FDA-approved drugs.
What Distinguishes Cord Tissue MSCs from Cord Blood Cells?
-
What distinguishes umbilical cord tissue MSCs from cord blood stem cells?
Cord blood is collected from the blood remaining in the cord and placenta after birth, serving primarily as a source of hematopoietic, or blood-forming, cells. In contrast, cord tissue MSCs are stromal cells harvested from Wharton’s jelly, the structural connective tissue surrounding the umbilical vessels.
-
How is donor safety maintained during birth tissue collection?
Collection occurs after a healthy, full-term birth with voluntary donor consent, requiring no medical procedure on the donor. Donor eligibility is determined through medical history screening and communicable-disease testing pursuant to 21 CFR Part 1271, Subpart C.
-
What questions should patients ask suppliers regarding cellular lots?
Patients and clinicians should verify the exact tissue source, donor eligibility determination protocols, isolation technique utilized, passage number, cumulative population doublings, and lot-specific viability testing results from an FDA-registered, cGTP-compliant facility.
References
- Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.
- Troyer DL, Weiss M. Wharton’s jelly-derived cells are a primitive stromal cell type. Stem Cells. 2008;26(3):591-599.
- Baksh D, Yao R, Tuan RS. Comparison of proliferative capacity and differentiation potential of human mesenchymal stem cells from umbilical cord and bone marrow. Stem Cells. 2007;25(6):1384-1392.
- Hass R, Kasper C, Böhm S, Jacobs R. Populations and characteristics of human mesenchymal stem cell from bone marrow and adipose tissue. Cell Commun Signal. 2011;9:12.
- Stolzing A, Jones E, McGonagle D, Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev. 2008;129(3):163-173.
- Salehinejad P, Alitheen NB, Ali AM, et al. Comparison of different methods for the isolation of mesenchymal stem cells from human umbilical cord Wharton’s jelly. In Vitro Cell Dev Biol Anim. 2012;48(2):75-83.
